Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 10, Pages 1540
Publisher
MDPI AG
Online
2019-10-11
DOI
10.3390/cancers11101540
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
- (2017) Caroline M. Robb et al. Oncotarget
- Tumor cells withKRASorBRAFmutations orERK5/MAPK7amplification are not addicted to ERK5 activity for cell proliferation
- (2016) Pamela A. Lochhead et al. CELL CYCLE
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5–AP-1 axis
- (2016) Kangmin Zhuang et al. Cell Death & Disease
- ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation
- (2016) Petrus R. de Jong et al. Nature Communications
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread—Identification of a Promising Novel therapeutic target
- (2015) Savita Bisht et al. Translational Oncology
- TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway
- (2015) Hong-Pei Yu et al. Scientific Reports
- PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines
- (2015) Alba Ginés et al. PLoS One
- Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
- (2014) D. Mouradov et al. CANCER RESEARCH
- Cdk5 activity in the brain - multiple paths of regulation
- (2014) K. Shah et al. JOURNAL OF CELL SCIENCE
- Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer
- (2014) Rebeca Sanz-Pamplona et al. Molecular Cancer
- Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells
- (2013) Fu-Ning Hsu et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
- (2013) Qian Liang et al. Scientific Reports
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Going out of the brain: Non-nervous system physiological and pathological functions of Cdk5
- (2011) Erick Contreras-Vallejos et al. CELLULAR SIGNALLING
- Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras
- (2011) J. P. Eggers et al. CLINICAL CANCER RESEARCH
- Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling
- (2010) Georg Feldmann et al. CANCER RESEARCH
- The cdk5 Kinase Regulates the STAT3 Transcription Factor to Prevent DNA Damage upon Topoisomerase I Inhibition
- (2010) Sandy Courapied et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
- (2010) Jun-Li Liu et al. MEDICAL ONCOLOGY
- Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy
- (2009) Eva Martinez-Balibrea et al. INTERNATIONAL JOURNAL OF CANCER
- Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
- (2009) A. Martinez-Cardus et al. MOLECULAR CANCER THERAPEUTICS
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search